Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Viking Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Viking Therapeutics Raises USD2.5 Million in Venture Financing 11
Partnerships 12
Kennedy Krieger Institute Enters into Research Agreement with Viking Therapeutics 12
Viking Therapeutics Enters into Research Agreement with Academic Medical Center 13
Licensing Agreements 14
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 14
Equity Offering 16
Viking Therapeutics Prices Public Offering of Shares for USD175.7 Million 16
Viking Therapeutics Raises USD77.6 Million in Public Offering of Shares 18
Viking Therapeutics Raises USD63.3 Million in Public offering of Shares 20
Viking Therapeutics Plans to Raise up to USD9.6 Million in Public Offering of Shares 22
Viking Therapeutics Raises USD14.8 Million in Public Offering of Shares 23
Viking Therapeutics to Raise USD15 Million in Public Offering of Shares 24
Viking Therapeutics Raises USD1.3 Million in Private Placement of Shares 25
Viking Therapeutics to Raise USD4.3 Million in Private Placement of Shares and Warrants 26
Viking Therapeutics Raises USD1.6 Million in Public Offering of Shares 27
Viking Therapeutics Raises USD1.8 Million in Private Placement of Shares 28
Viking Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 29
Viking Therapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD10.8 Million 30
Viking Therapeutics Completes Exercise of Underwriter’s Over Allotment Option for IPO of Shares for USD27.6 Million 32
Debt Offering 34
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 34
Viking Therapeutics Inc – Key Competitors 35
Viking Therapeutics Inc – Key Employees 36
Viking Therapeutics Inc – Locations And Subsidiaries 37
Head Office 37
Recent Developments 38
Financial Announcements 38
Aug 09, 2018: Viking Therapeutics reports second quarter 2018 financial results and provides corporate update 38
May 09, 2018: Viking Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 40
Mar 07, 2018: Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update 42
Nov 08, 2017: Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 44
Aug 09, 2017: Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 46
May 10, 2017: Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 48
Mar 21, 2017: Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 50
Corporate Communications 52
Jul 06, 2017: Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors 52
Product News 53
10/24/2017: Viking Therapeutics Presents Results from In Vivo Study of VK2809 in Biopsy-Confirmed Non-Alcoholic Steatohepatitis at the Annual Meeting of the American Association for the Study of Liver Diseases 53
10/23/2017: Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy at the 87th Annual Meeting of the American Thyroid Association 55
10/04/2017: Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) 57
06/06/2017: Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) 58
Clinical Trials 60
Jun 05, 2018: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease 60
Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture 61
Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings 63
Sep 11, 2017: Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) 65
Sep 07, 2017: Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia at the 13th International Congress of Inborn Errors of Metabolism 66
Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture 68
Feb 09, 2017: Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) 69
Appendix 70
Methodology 70
About GlobalData 70
Contact Us 70
Disclaimer 70
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Viking Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Viking Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Viking Therapeutics Raises USD2.5 Million in Venture Financing 11
Kennedy Krieger Institute Enters into Research Agreement with Viking Therapeutics 12
Viking Therapeutics Enters into Research Agreement with Academic Medical Center 13
Viking Therapeutics Amends Licensing Agreement With Ligand Pharma 14
Viking Therapeutics Prices Public Offering of Shares for USD175.7 Million 16
Viking Therapeutics Raises USD77.6 Million in Public Offering of Shares 18
Viking Therapeutics Raises USD63.3 Million in Public offering of Shares 20
Viking Therapeutics Plans to Raise up to USD9.6 Million in Public Offering of Shares 22
Viking Therapeutics Raises USD14.8 Million in Public Offering of Shares 23
Viking Therapeutics to Raise USD15 Million in Public Offering of Shares 24
Viking Therapeutics Raises USD1.3 Million in Private Placement of Shares 25
Viking Therapeutics to Raise USD4.3 Million in Private Placement of Shares and Warrants 26
Viking Therapeutics Raises USD1.6 Million in Public Offering of Shares 27
Viking Therapeutics Raises USD1.8 Million in Private Placement of Shares 28
Viking Therapeutics Raises USD0.5 Million in First Tranche of Private Placement of Shares 29
Viking Therapeutics Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD10.8 Million 30
Viking Therapeutics Completes Exercise of Underwriter's Over Allotment Option for IPO of Shares for USD27.6 Million 32
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 34
Viking Therapeutics Inc, Key Competitors 35
Viking Therapeutics Inc, Key Employees 36
List of Figures
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Viking Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9